10 completed, 1 terminated, 1 unknown. 12 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 10, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow netarsudil: new trials by email Literature Review of netarsudil trials Research Report on netarsudil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution - Ocular Hypertension, Open Angle Glaucoma | Phase 3 | Completed | Alcon Research | 489 | 2025-09-02 | 2026-04-21 |
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma | Phase 2 / Phase 3 | Completed | University Hospital Dubrava | 50 | 2025-05-12 | 2026-09-09 |
| A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 / Phase 3 | Unknown | Wills Eye | 80 | 2023-02-06 | 2024-07-30 |
| Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration Netarsudil, Placebo - Fuchs' Endothelial Dystrophy | Phase 2 / Phase 3 | Terminated | Price Vision Group | 19 | 2019-07-22 | 2023-02-06 |
| Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation Netarsudil, Placebo - Fuchs' Endothelial Dystrophy, Bullous Keratopathy | Phase 3 | Completed | Cornea Research Foundation of America | 120 | 2017-09-05 | 2021-02-12 |
| Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension Netarsudil/Latanoprost 0.02%/0.005%, GANFORT® - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 436 | 2017-09-05 | 2022-01-31 |
| Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005% - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 750 | 2016-02-01 | 2019-05-21 |
| Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005% - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 718 | 2015-09-18 | 2019-06-04 |
| Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Aerie Pharmaceuticals | 708 | 2015-09-01 | 2018-04-06 |
| Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID - Ocular Hypertension, Glaucoma | Phase 3 | Completed | Aerie Pharmaceuticals | 93 | 2014-09-01 | 2018-04-06 |
| Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Aerie Pharmaceuticals | 756 | 2014-07-01 | 2018-04-06 |
| Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Aerie Pharmaceuticals | 411 | 2014-07-01 | 2018-04-13 |
Ocular Hypertension (8) · Glaucoma, Open-Angle (7) · Glaucoma (5) · Fuchs' Endothelial Dystrophy (2) · Corneal Edema (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Retinal Detachment (1) · Vitreoretinopathy, Proliferative (1)
Aerie Pharmaceuticals (7) · Alcon Research (1) · Cornea Research Foundation of America (1) · Price Vision Group (1) · University Hospital Dubrava (1) · Wills Eye (1)
United States (10) · Austria (1) · Belgium (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Latvia (1) · Poland (1) · Spain (1) · United Kingdom (1)
Theresa Heah, MD (4) · Francis W Price, Jr, MD (2) · Theresa Heah, MD, MBA (2) · Jason Hsu, MD (1) · Josip Pavan, MD, PhD (1) · Michelle Senchyna (1)
PMID 32166538, PMID 31981106, PMID 33045216, PMID 33250082, PMID 42568743